Mouse models of Kras-mutant colorectal cancer

项目总结/摘要 结直肠癌（CRC）每年导致超过50，000名美国人死亡。氟尿嘧啶为基础的治疗仍然是 在过去的五年中，没有批准用于CRC的靶向治疗。 KRAS癌基因的突变激活-发生在40%以上的病例中-是癌症的主要来源。 对CRC中常规和靶向治疗的内在和获得性耐药性。由于没有 直接或间接靶向K-Ras或其下游效应子通路、KRAS突变的有效疗法 是CRC治疗的最大障碍。 癌症基因组的大规模测序显示，在表达 在突变型K-Ras中，KRAS等位基因的多样性大于任何其他类型的癌症。流行病学研究 表明生存率和对治疗的反应取决于患者的KRAS基因型。 这表明K-Ras癌蛋白的不同突变形式可以表现出不同的致癌性， 特性.然而，等位基因特异性行为的实验验证从未实现。我们将使用 主要的人类和小鼠类器官和基因工程小鼠模型，以解决三个关键问题 与K-Ras致瘤性有关的问题：（1）K-Ras的不同突变形式在它们的能力方面是否等同， 促进结直肠癌的发生和发展？(2)KRAS和其他基因之间的相互作用 等位基因特异性基因(3)K-Ras的突变形式如何影响非细胞肿瘤微环境？ 自主的方式来促进癌症的进展？ 这项工作的最终目标是破译“KRAS等位基因密码”，以确定治疗性的 对表达特定K-Ras突变体的癌症有效的策略。精准医疗， 医生根据患者癌症中突变的基因量身定制患者的治疗，需要这种水平的 了解，特别是对于像K-Ras这样无法用直接抑制剂靶向的突变癌蛋白。

Project Summary/Abstract Colorectal cancer (CRC) kills more than 50,000 Americans each year. Fluorouracil-based therapy remains the standard of care and there have been no targeted therapies approved for use in CRC in the past half decade. Mutational activation of the KRAS oncogene – which occurs more than in 40% of cases – is a major source of intrinsic and acquired resistance to both conventional and targeted therapies in CRC. Since there are no effective therapies that directly or indirectly target K-Ras or its downstream effector pathways, KRAS mutation is the single greatest barrier to medical treatment for CRC. Large scale sequencing of cancer genomes has revealed that, among those 40% of CRCs that express mutant K-Ras, the diversity of KRAS alleles is greater than in any other type of cancer. Epidemiological studies demonstrate that survival and response to therapy varies depending on the KRAS genotype of the patient's cancer, suggesting that different mutant forms of the K-Ras oncoprotein could exhibit distinct oncogenic properties. Experimental validation of allele-specific behaviors has never been achieved, however. We will use primary human and mouse organoids and genetically engineered mouse models to address three key questions relating to K-Ras oncogenicity: (1) Are different mutant forms of K-Ras equivalent in their ability to promote colorectal cancer initiation and progression? (2) Are genetic interactions between KRAS and other genes allele-specific? (3) How do mutant forms of K-Ras influence the tumor microenvironment in a non-cell- autonomous manner to promote cancer progression? The ultimate goal of this work is to decipher the “KRAS Allele Code” in order to identify therapeutic strategies that are effective for cancers expressing specific K-Ras mutants. Precision medicine, where a physician tailors a patient's therapy to the genes that are mutated in his/her cancer, requires this level of understanding, especially for mutant oncoprotein that, like K-Ras, cannot be targeted with direct inhibitors.